Zyprexa 3rd-Party Payers' Class Bid Draws Flak
The multidistrict litigation over Eli Lilly & Co.'s anti-psychotic drug Zyprexa is "fundamentally different" from the ongoing putative class action over the drug industry's average wholesale prices, and a decision in...To view the full article, register now.
Already a subscriber? Click here to view full article